Novanta Q2 Revenue Climbs 10.3% to $265.8M; Riverpoint Medical Acquisition Closes
NOVT sits 61% above its 52-week low of $98.27.
Summary
Novanta reported Q2 2026 revenue of $265.8M (+10.3% YoY) and diluted EPS of $0.30. The $1.2B Riverpoint Medical acquisition closed in July, funded by $616M in new debt and cash. A $300M private placement was completed in June.
Key Events · Earnings and Guidance · NOVT
-
Q2 Revenue and Earnings Growth
Revenue increased 10.3% to $265.8 million, with diluted EPS of $0.30 versus $0.12 in the prior year. Operating income rose 21.1% to $18.1 million.
-
Riverpoint Medical Acquisition Closed
On July 23, 2026, Novanta completed the $1.2 billion acquisition of Riverpoint Medical, a leader in minimally invasive surgical consumables, funded by $616 million in new debt and cash on hand.
-
$300M Private Placement Completed
In June 2026, Novanta issued 2.14 million common shares at $140.00 per share in a private placement, raising net proceeds of approximately $287.6 million.
-
Strong Cash Flow and Balance Sheet
Operating cash flow was $116.5 million for the first six months, up from $46.8 million. Cash and equivalents stood at $718.7 million as of July 3, 2026, with total debt of $229.7 million.
Analysis · NOVT · Manufacturing
A strong second quarter saw revenue advance 10.3% to $265.8 million, while diluted EPS reached $0.30, up from $0.12 a year ago. Operating cash flow more than doubled to $116.5 million, and the balance sheet reflects $718.7 million in cash against $229.7 million in total debt. The period also included the completion of a $300 million private placement and, on July 23, 2026, the closing of the $1.2 billion Riverpoint Medical acquisition — a transformative deal that significantly expands the medical consumables business. Credit agreement amendments provide additional financial flexibility. Together, the results and the acquisition closing are material events that reshape the company's financial profile and growth trajectory.
At the time of this filing, NOVT was trading at $158.00 on NASDAQ in the Manufacturing sector, with a market capitalization of approximately $5.5B. The 52-week trading range was $98.27 to $171.85. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.